HTC
DNTH icon

Hershey Trust Company’s Dianthus Therapeutics DNTH Stock Holding History

Hershey Trust Company’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,268
Closed -$148K – 42
2021
Q3 		$148K Buy
+1,268
New +$148K ﹤0.01% 24

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Hershey Trust Company's DNTH Position: Q4 2021 in Review

Hershey Trust Company sold out of Dianthus Therapeutics (DNTH) in Q4 2021, closing a stake of 1,268 shares — an estimated $148K sold.

Hershey Trust Company first reported a position in DNTH in Q3 2021 and held it in 1 quarter. The position peaked at $148K in Q3 2021. 94 funds tracked by Wall St. Rank hold DNTH as of Q4 2021.

  • Hershey Trust Company reported no remaining Dianthus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Hershey Trust Company sold 1,268 Dianthus Therapeutics shares in Q4 2021, an estimated $148K.
  • Hershey Trust Company first reported a position in Dianthus Therapeutics in Q3 2021 and held it in 1 quarter.
  • Hershey Trust Company's Dianthus Therapeutics position peaked at $148K in Q3 2021.
  • 94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2021.

Based on Hershey Trust Company's 13F filing for Q4 2021, filed 11 Feb 2022.